Study of T Specific Immune Response Against Delta-CD20 Peptide in Hematological Malignancies B

Inclusion Criteria: * For all patient : •Written informed consent * For Cohort A : * Patient with hematological malignancy of high grade phenotype B (non Hodgkin's lymphoma diffuse large cell) or low grade (mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma or Waldenstrom disease), regardless the initial extension stage. * Histologically or cytologically and immunophenotypical confirmed * Patient candidate to a second-line or more therapy * First-line treatment with rituximab * For Cohort B : * Absence of prior treatment with an anti-CD20 antibody * Histologically or cytologically and immunophenotypical confirmed Exclusion Criteria: * For all patients : * Patient with any medical or psychiatric condition or disease, * Patient under guardianship, curatorship or under the protection of justice and pregnant women * For Cohort A : * Patient with chronic lymphocytic leukemia * Patient with indolent lymphoma relapsed more than 1 year after treatment with Rituximab * Patient allogeneic hematopoietic cells * Patient with linked lymphoproliferative syndrome with congenital immunosuppression (eg SCID, XLP ...) or acquired (post-transplant lymphoma)